|
1
|
Bouiller K, Zayet S, Lalloz PE, Potron A,
Gendrin V, Chirouze C and Klopfenstein T: Efficacy and safety of
oral fosfomycin-trometamol in male urinary tract infections with
multidrug-resistant enterobacterales. Antibiotics (Basel).
11(198)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kwan ACF and Beahm NP: Fosfomycin for
bacterial prostatitis: A review. Int J Antimicrob Agents.
56(106106)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Erdem H, Hargreaves S, Ankarali H,
Caskurlu H, Ceviker SA, Bahar-Kacmaz A, Meric-Koc M, Altindis M,
Yildiz-Kirazaldi Y, Kizilates F, et al: Managing adult patients
with infectious diseases in emergency departments: International
ID-IRI study. J Chemother. 33:302–318. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
El-Sokkary R, Uysal S, Erdem H, Kullar R,
Pekok AU, Amer F, Grgić S, Carevic B, El-Kholy A, Liskova A, et al:
Profiles of multidrug-resistant organisms among patients with
bacteremia in intensive care units: An international ID-IRI survey.
Eur J Clin Microbiol Infect Dis. 40:2323–2334. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marino A, Munafò A, Zagami A, Ceccarelli
M, Di Mauro R, Cantarella G, Bernardini R, Nunnari G and Cacopardo
B: Ampicillin plus ceftriaxone regimen against enterococcus
faecalis endocarditis: A literature review. J Clin Med.
10(4594)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Magiorakos AP, Srinivasan A, Carey RB,
Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter
G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively
drug-resistant and pandrug-resistant bacteria: An international
expert proposal for interim standard definitions for acquired
resistance. Clin Microbiol Infect. 18:268–281. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aris P, Boroumand MA, Rahbar M and
Douraghi M: The activity of fosfomycin against extended-spectrum
beta-lactamase-producing isolates of enterobacteriaceae recovered
from urinary tract infections: A single-center study over a period
of 12 years. Microb Drug Resist. 24:607–612. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Falagas ME, Kastoris AC, Kapaskelis AM and
Karageorgopoulos DE: Fosfomycin for the treatment of
multidrug-resistant, including extended-spectrum beta-lactamase
producing, enterobacteriaceae infections: A systematic review.
Lancet Infect Dis. 10:43–50. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhanel GG, Zhanel MA and Karlowsky JA:
Oral Fosfomycin for the treatment of acute and chronic bacterial
prostatitis caused by multidrug-resistant Escherichia coli.
Can J Infect Dis Med Microbiol. 2018(1404813)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Marino A, Munafò A, Zagami A, Ceccarelli
M, Campanella E, Cosentino F, Moscatt V, Cantarella G, Di Mauro R,
Bernardini R, et al: Ampicillin plus ceftriaxone therapy against
enterococcus faecalis endocarditis: A case report, guidelines
considerations, and literature review. IDCases.
28(e01462)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Devrim I, Erdem H, El-Kholy A, Almohaizeie
A, Logar M, Rahimi BA, Amer F, Alkan-Ceviker S, Sonmezer MC,
Belitova M, et al: Analyzing central-line associated bloodstream
infection prevention bundles in 22 countries: The results of ID-IRI
survey. Am J Infect Control. (S0196-6553(22)00138-9)2022.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
12
|
Dijkmans AC, Zacarías NVO, Burggraaf J,
Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J and
Kamerling IMC: Fosfomycin: Pharmacological, clinical and future
perspectives. Antibiotics (Basel). 6(24)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
MIC EUCAST: Antimicrobial Wild Type
Distributions of Microorganisms. Available from: https://mic.eucast.org/search/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=100&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50.
Accessed May 9, 2022.
|
|
14
|
Sastry S and Doi Y: Fosfomycin: Resurgence
of an old companion. J Infect Chemother. 22:273–280.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gardiner BJ, Mahony AA, Ellis AG,
Lawrentschuk N, Bolton DM, Zeglinski PT, Frauman AG and Grayson ML:
Is fosfomycin a potential treatment alternative for
multidrug-resistant gram-negative prostatitis? Clin Infect Dis.
58:e101–e105. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fan L, Shang X, Zhu J, Ma B and Zhang Q:
Pharmacodynamic and pharmacokinetic studies and prostatic tissue
distribution of fosfomycin tromethamine in bacterial prostatitis or
normal rats. Andrologia. 50(e13021)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Takasaki N, Ra S, Okada S, Sakakibara T,
Tonami H, Kitagawa Y and Miyazaki S: Transference of antibiotics
into prostatic tissues: Sampling method by transurethral resection
for the measurement of the concentration of antibiotics in the
prostatic tissues. Hinyokika Kiyo. 32:969–975. 1986.PubMed/NCBI(In Japanese).
|
|
18
|
Falagas ME, Vouloumanou EK, Samonis G and
Vardakas KZ: Fosfomycin. Clin Microbiol Rev. 29:321–347.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zykov IN, Samuelsen Ø, Jakobsen L,
Småbrekke L, Andersson DI, Sundsfjord A and Frimodt-Møller N:
Pharmacokinetics and pharmacodynamics of fosfomycin and its
activity against extended-spectrum-β-lactamase-, plasmid-mediated
AmpC-, and carbapenemase-producing Escherichia coli in a
murine urinary tract infection model. Antimicrob Agents Chemother.
62:e02560–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Michalopoulos AS, Livaditis IG and
Gougoutas V: The revival of fosfomycin. Int J Infect Dis.
15:e732–e739. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Okazaki M, Suzuki K, Asano N, Araki K,
Shukuya N, Egami T, Higurashi Y, Morita K, Uchimura H and Watanabe
T: Effectiveness of fosfomycin combined with other antimicrobial
agents against multidrug-resistant Pseudomonas aeruginosa
isolates using the efficacy time index assay. J Infect Chemother.
8:37–42. 2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Takahashi K and Kanno H: Synergistic
activities of combinations of beta-lactams, fosfomycin, and
tobramycin against Pseudomonas aeruginosa. Antimicrob Agents
Chemother. 26:789–791. 1984.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sultan A, Rizvi M, Khan F, Sami H, Shukla
I and Khan HM: Increasing antimicrobial resistance among
uropathogens: Is fosfomycin the answer? Urol Ann. 7:26–30.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vardakas KZ, Legakis NJ, Triarides N and
Falagas ME: Susceptibility of contemporary isolates to fosfomycin:
A systematic review of the literature. Int J Antimicrob Agents.
47:269–285. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Castañeda-García A, Blázquez J and
Rodríguez-Rojas A: Molecular mechanisms and clinical impact of
acquired and intrinsic fosfomycin resistance. Antibiotics (Basel).
2:217–236. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mihailescu R, Furustrand Tafin U, Corvec
S, Oliva A, Betrisey B, Borens O and Trampuz A: High activity of
Fosfomycin and rifampin against methicillin-resistant
Staphylococcus aureus biofilm in vitro and in an
experimental foreign-body infection model. Antimicrob Agents
Chemother. 58:2547–2553. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chai D, Liu X, Wang R, Bai Y and Cai Y:
Efficacy of linezolid and fosfomycin in catheter-related biofilm
infection caused by methicillin-resistant Staphylococcus
aureus. Biomed Res Int. 2016(6413982)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Oliva A, Curtolo A, Volpicelli L, Cogliati
Dezza F, De Angelis M, Cairoli S, Dell'Utri D, Goffredo BM, Raponi
G and Venditti M: Synergistic meropenem/vaborbactam plus fosfomycin
treatment of KPC producing K. Pneumoniae septic thrombosis
unresponsive to ceftazidime/avibactam: From the bench to the
bedside. Antibiotics (Basel). 10(781)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Flamm RK, Rhomberg PR, Lindley JM, Sweeney
K, Ellis-Grosse EJ and Shortridge D: Evaluation of the bactericidal
activity of fosfomycin in combination with selected antimicrobial
comparison agents tested against gram-negative bacterial strains by
using time-kill curves. Antimicrob Agents Chemother. 63:e02549–18.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Papp-Wallace KM, Zeiser ET, Becka SA, Park
S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE,
et al: Ceftazidime-avibactam in combination with fosfomycin: A
novel therapeutic strategy against multidrug-resistant
Pseudomonas aeruginosa. J Infect Dis. 220:666–676.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cuba GT, Rocha-Santos G, Cayô R, Streling
AP, Nodari CS, Gales AC, Pignatari ACC, Nicolau DP and Kiffer CRV:
In vitro synergy of ceftolozane/tazobactam in combination with
fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
J Antimicrob Chemother. 75:1874–1878. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Samonis G, Maraki S, Karageorgopoulos DE,
Vouloumanou EK and Falagas ME: Synergy of fosfomycin with
carbapenems, colistin, netilmicin, and tigecycline against
multidrug-resistant Klebsiella pneumoniae, Escherichia
coli, and Pseudomonas aeruginosa clinical isolates. Eur
J Clin Microbiol Infect Dis. 31:695–701. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Drusano GL, Neely MN, Yamada WM, Duncanson
B, Brown D, Maynard M, Vicchiarelli M and Louie A: The combination
of fosfomycin plus meropenem is synergistic for Pseudomonas
aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob
Agents Chemother. 62:e01682–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Leelasupasri S, Santimaleeworagun W and
Jitwasinkul T: Antimicrobial susceptibility among colistin,
sulbactam, and fosfomycin and a synergism study of colistin in
combination with sulbactam or fosfomycin against clinical isolates
of carbapenem-resistant acinetobacter baumannii. J Pathog.
2018(3893492)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhao M, Bulman ZP, Lenhard JR, Satlin MJ,
Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, et
al: Pharmacodynamics of colistin and fosfomycin: A ‘treasure trove’
combination combats KPC-producing Klebsiella pneumoniae. J
Antimicrob Chemother. 72:1985–1990. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lee YC, Chen PY, Wang JT and Chang SC:
Prevalence of fosfomycin resistance and gene mutations in clinical
isolates of methicillin-resistant Staphylococcus aureus.
Antimicrob Resist Infect Control. 9(135)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Maraki S, Samonis G, Rafailidis PI,
Vouloumanou EK, Mavromanolakis E and Falagas ME: Susceptibility of
urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother.
53:4508–4510. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Keating GM: Fosfomycin trometamol: A
review of its use as a single-dose oral treatment for patients with
acute lower urinary tract infections and pregnant women with
asymptomatic bacteriuria. Drugs. 73:1951–1966. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Saltoglu N, Karali R, Yemisen M, Ozaras R,
Balkan II, Mete B, Tabak F, Mert A, Hondur N and Ozturk R:
Comparison of community-onset healthcare-associated and
hospital-acquired urinary infections caused by extended-spectrum
beta-lactamase-producing Escherichia coli and antimicrobial
activities. Int J Clin Pract. 69:766–770. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu HY, Lin HC, Lin YC, Yu SH, Wu WH and
Lee YJ: Antimicrobial susceptibilities of urinary extended-spectrum
beta-lactamase-producing Escherichia coli and
Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a
teaching hospital in Taiwan. J Microbiol Immunol Infect.
44:364–368. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Karageorgopoulos DE, Wang R, Yu XH and
Falagas ME: Fosfomycin: Evaluation of the published evidence on the
emergence of antimicrobial resistance in Gram-negative pathogens. J
Antimicrob Chemother. 67:255–268. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
European Society of Clinical Microbiology
and Infectious Diseases Fosfomycin Trometamol-Rationale for the
EUCAST Clinical Breakpoints, version 1.0, pp1-8, 2013.
|
|
43
|
van Mens SP, Ten Doesschate T,
Kluytmans-van den Bergh MF, Mouton JW, Rossen JW, Verhulst C,
Bonten MJ and Kluytmans JA: Fosfomycin etest for
enterobacteriaceae: Interobserver and interlaboratory agreement.
Int J Antimicrob Agents. 52:678–681. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Karlowsky JA, Baxter MR, Golden AR, Adam
HJ, Walkty A, Lagacé-Wiens PR and Zhanel GG: Use of fosfomycin
etest to determine in vitro susceptibility of clinical isolates of
enterobacterales other than Escherichia coli, nonfermenting
gram-negative bacilli, and gram-positive cocci. J Clin Microbiol.
59(e0163521)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
van den Bijllaardt W, Schijffelen MJ,
Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, Le TN,
Overdevest I, Stals F, Voorn P, et al: Susceptibility of ESBL
Escherichia coli and Klebsiella pneumoniae to
fosfomycin in the Netherlands and comparison of several testing
methods including etest, MIC test strip, Vitek2, phoenix and disc
diffusion. J Antimicrob Chemother. 73:2380–2387. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Aprile A, Scalia G, Stefani S and
Mezzatesta ML: In vitro fosfomycin study on concordance of
susceptibility testing methods against ESBL and
carbapenem-resistant enterobacteriaceae. J Glob Antimicrob Resist.
23:286–289. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Campanile F, Wootton M, Davies L, Aprile
A, Mirabile A, Pomponio S, Demetrio F, Bongiorno D, Walsh TR,
Stefani S and Mezzatesta ML: Gold standard susceptibility testing
of fosfomycin in Staphylococcus aureus and enterobacterales
using a new agar dilution panel®. J Glob Antimicrob
Resist. 23:334–337. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Parisio EM, Camarlinghi G, Coppi M,
Niccolai C, Antonelli A, Nardone M, Vettori C, Giani T, Mattei R
and Rossolini GM: Evaluation of the commercial AD fosfomycin test
for susceptibility testing of multidrug-resistant enterobacterales
and Pseudomonas aeruginosa. Clin Microbiol Infect: Dec 4,
2020 (Epub ahead of print). doi: https://doi.org/10.1016/j.cmi.2020.11.029.
|
|
49
|
European Society of Clinical Microbiology
and Infectious Diseases EUCAST: Clinical Breakpoints and Dosing of
Antibiotics. Available from: https://www.eucast.org/clinical_breakpoints/.
Accessed May 9, 2022.
|
|
50
|
Martín-Gutiérrez G, Docobo-Pérez F,
Rodríguez-Martínez JM, Pascual A, Blázquez J and Rodriguez-Beltrán
J: Detection of low-level fosfomycin-resistant variants by
decreasing glucose-6-phosphate concentration in fosfomycin
susceptibility determination. Antibiotics (Basel).
9(802)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cattoir V and Guérin F: How is fosfomycin
resistance developed in Escherichia coli? Future Microbiol.
13:1693–1696. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Karaiskos I, Galani L, Sakka V, Gkoufa A,
Sopilidis O, Chalikopoulos D, Alivizatos G and Giamarellou E: Oral
fosfomycin for the treatment of chronic bacterial prostatitis. J
Antimicrob Chemother. 74:1430–1437. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Denes E: Prolonged course of
fosfomycin-trometamol for chronic prostatitis: An unknown good
option. Scand J Urol. 55:344–345. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cai T, Tamanini I, Mattevi D, Verze P,
Palmieri A, Malossini G, Mirone V, Novelli A, Tascini C and
Johansen TE: Fosfomycin trometamol and N-acetyl-L-cysteine as
combined oral therapy of difficult-to-treat chronic bacterial
prostatitis: Results of a pilot study. Int J Antimicrob Agents.
56(105935)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Los-Arcos I, Pigrau C, Rodríguez-Pardo D,
Fernández-Hidalgo N, Andreu A, Larrosa N and Almirante B: Long-term
fosfomycin-tromethamine oral therapy for difficult-to-treat chronic
bacterial prostatitis. Antimicrob Agents Chemother. 60:1854–1858.
2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Grayson ML, Macesic N, Trevillyan J, Ellis
AG, Zeglinski PT, Hewitt NH, Gardiner BJ and Frauman AG: Fosfomycin
for treatment of prostatitis: New tricks for old dogs. Clin Infect
Dis. 61:1141–1143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shrestha NK, Amuh D, Goldman M, Riebel WJ
and Walton*Tomford J: Treatment of a complicated
vancomycin-resistant enterococcal urinary tract infection with
fosfomycin. Infect Dis Clin Pract. 9:368–371. 2000.
|
|
58
|
Celesia BM, Marino A, Borracino S,
Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo
B and Panarello G: Successful extracorporeal membrane oxygenation
treatment in an acquired immune deficiency syndrome (AIDS) patient
with acute respiratory distress syndrome (ARDS) complicating
pneumocystis jirovecii pneumonia: A challenging case. Am J Case
Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Matsumoto M and Yamamoto S: AAUS guideline
for acute bacterial prostatitis 2021. J Infect Chemother.
27:1277–1283. 2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Marino A, Cosentino F, Ceccarelli M,
Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G,
Benanti F, et al: Entecavir resistance in a patient with
treatment-naïve HBV: A case report. Mol Clin Oncol.
14(113)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Celesia BM, Marino A, Del Vecchio RF,
Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it safe
and cost saving to defer the CD4+ cell count monitoring
in stable patients on art with more than 350 or 500 cells/µl?
Mediterr J Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar
|
